Nanologica AB (FRA:4YD) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4YD Nanologica AB FRA:4YD
45 GF Score
Price €0.03
GF Value €0.30
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Nanologica AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:4YD
45GF Score
Nanologica AB FRA:4YD
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nanologica AB (FRA:4YD) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of €0.03 is trading 89.5% below its estimated GF Value™ of €0.30. GuruFocus considers Nanologica AB to be Modestly Undervalued.

Key valuation signals for FRA:4YD:

  • FFO:
  • GF Value™: €0.30 vs. price of €0.03 (89.5% below fair value)
  • GF Score™: 45/100 with 9 warning signs

No single metric tells the full story. See the FRA:4YD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanologica AB Business Description

Other Exchanges NICA:Sweden
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score

Get the complete analysis for FRA:4YD

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.30
GF Value